Document is current
Any future updates will be listed below
-
Authors
Paik, Jisun https://orcid.org/0000-0001-5628-7723
Kim, Andy https://orcid.org/0009-0007-1566-9283
Fogassy, Kevin
Snyder, Jessica M.
Brabb, Thea https://orcid.org/0000-0001-5849-1971
Dill-McFarland, Kimberly A.
He, Qianchuan
Amory, John K.
- License Information
-
More Information
Article History
Received: 1 August 2024
Revised: 25 October 2024
Accepted: 1 November 2024
First Online: 11 November 2024
Competing interests
: Authors (Amory and Paik) have a patent for FSI-TN42. Dill-McFarland reports consulting fees from Seattle BioSoftware. Kim, Fogassy, Snyder, Brabb, and He declare no potential competing interests. Dr. Amory receives research funds from Ferring Pharmaceutics and Celldex Therapeutics and serves as a consultant for NEXT Life Sciences.
: All experimental procedures involving animals were conducted following the relevant guidelines and regulations, including Animal welfare Act and Animal Welfare regulations, Public Health Service Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the University of Washington (Protocol 4038-01).
